Arbutus Biopharma Gains 0.7% as FDA Lifts Hold on AB‑101, Boosting Investor Optimism
Arbutus Biopharma’s stock rises 0.7% as the FDA lifts the clinical hold on AB‑101, a PD‑L1 inhibitor, hinting at accelerated Hepatitis B trials and potential upside.
- ARBUTUS BIOPHARMA CORP
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read